Teduglutide: a review of its use in short bowel syndrome

被引:3
|
作者
Burgos Pelaez, Rosa [1 ]
Cuerda Compes, Ma Cristina [2 ]
Garcia-Luna, Pedro P. [3 ]
Martinez Faedo, Ceferino [4 ]
Mauri Roca, Silvia [5 ]
Moreno Villares, Jose Manuel [6 ]
Virgili Casas, M. Nuria [7 ]
Wanden-Berghe, Carmina [8 ]
机构
[1] Hosp Univ Vall dHebron, Unidad Soporte Nutr, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
[2] Hosp Gen Univ Gregorio Maranon, Unidad Nutr, Madrid, Spain
[3] Hosp Univ Virgen del Rocio, U Nutr UGEN, Seville, Spain
[4] HUCA, Unidad Nutr, Oviedo, Spain
[5] Hosp Univ Doctor Josep Trueta, Girona, Spain
[6] Hosp Univ 12 Octubre, Nutr Clin, Madrid, Spain
[7] Hosp Univ Bellvitge, Serv Endocrinol & Nutr, Unidad Nutr & Dietet, Barcelona, Spain
[8] Hosp Gen Univ Alicante, ISABIAL FISABIO, Unidad Hospitalizac Domicilio, Alicante, Spain
关键词
Intestinal failure; Teduglutide; Short-bowel syndrome; GLP-2; Parenteral nutrition; HOME PARENTERAL-NUTRITION; INTESTINAL FAILURE; ADULT PATIENTS; MANAGEMENT; PHARMACOKINETICS; ADMINISTRATIONS; REHABILITATION; COMPLICATIONS; MULTICENTER; DEPENDENCE;
D O I
10.20960/nh.400
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Introduction: Long-term Parenteral Support (PS) can be associated with serious complications, with a significant deterioration in the quality of life of patients with short bowel syndrome (SBS). Teduglutide is a recombinant analogue of glucagon-like peptide-2; it belongs to a novel therapeutic family and represents the first non-symptomatic approach against SBS. Objectives: To review the non-clinical and clinical data on efficacy and safety of teduglutide. Results: Teduglutide approval was based on results from a pivotal Phase III, 24-week, double-blind, placebo-controlled study (STEPS). SBS patients dependent on PS >= 3 times/week for >= 12 months received 0.05 mg/kg teduglutide (n = 43) or placebo (n = 43) 1 time/day. At week 24 there were significantly more responders in the teduglutide group vs. placebo (63 vs. 30%; p = 0.002). The overall mean reduction vs. PS baseline volume at week 24 was significantly higher with teduglutide vs. placebo (4.4 vs. 2.3 l/ week, p < 0.001). At week 24 the need for PS was reduced in at least 1 day in 54% of patients treated with teduglutide vs. 23% with placebo. Of the total of patients who received teduglutide in phase III trials (n = 134), 12% achieved complete autonomy from PS. Subcutaneous teduglutide was generally well tolerated. Conclusions: Teduglutide has been shown to enhance intestinal absorptive capacity and significantly reduce PS dependency, even achieving independency in some patients.
引用
收藏
页码:969 / 977
页数:9
相关论文
共 50 条